Piramal Pharma (NSE:PPLPHARMA) Debt-to-Equity: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
52 GF Score
Price ₹212.49
GF Value ₹191.86
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Piramal Pharma Debt-to-Equity?

Piramal Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Piramal Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Piramal Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Piramal Pharma's Debt-to-Equity or its related term are showing as below:

NSE:PPLPHARMA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04   Med: 0.6   Max: 0.83
Current: 0.7

During the past 6 years, the highest Debt-to-Equity Ratio of Piramal Pharma was 0.83. The lowest was 0.04. And the median was 0.60.

NSE:PPLPHARMA's Debt-to-Equity is ranked worse than
78.08% of 812 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs NSE:PPLPHARMA: 0.70

Piramal Pharma  (NSE:PPLPHARMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Piramal Pharma Debt-to-Equity Related Terms

Piramal Pharma Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Debt-to-Equity Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
Get a 7-Day Free Trial 0.62 0.83 0.60 0.60 0.70

Piramal Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.60 N/A 0.70 N/A

NSE:PPLPHARMA vs ZTS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Debt-to-Equity falls into.


NSE:PPLPHARMA
52GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Piramal Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(12391.8 + 44354) / 81625.8
=0.70

Piramal Pharma's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued. The current stock price of ₹212.49 is trading 10.8% above its estimated GF Value™ of ₹191.86. GuruFocus considers Piramal Pharma to be Modestly Overvalued.

Key valuation signals for NSE:PPLPHARMA:

  • Debt-to-Equity: N/A
  • GF Value™: ₹191.86 vs. price of ₹212.49 (10.8% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
52GF Score

Get the complete analysis for NSE:PPLPHARMA

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹212.49
Price
₹191.86
GF Value